华纳药厂：子公司原料药获上市申请批准通知书

Core Insights - Warner Pharmaceuticals announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride and Levonordefrin Tartrate [1] Product Development - Isoproterenol Hydrochloride is indicated for the treatment of cardiogenic or infectious shock, while Levonordefrin Tartrate is used to manage blood pressure in acute hypotensive states [1] Competitive Advantage - The approval will enrich the company's product line and enhance its core competitiveness in the pharmaceutical market [1]